AbbVie’s “Buy” Rating Reaffirmed at Jefferies Group (ABBV)
AbbVie (NASDAQ:ABBV)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a report issued on Friday, ARN reports.
AbbVie (NASDAQ:ABBV) traded down 0.31% on Friday, hitting $45.54. 1,118,964 shares of the company’s stock traded hands. AbbVie has a one year low of $33.33 and a one year high of $48.42. The stock’s 50-day moving average is $44.90 and its 200-day moving average is $44.01. The company has a market cap of $72.200 billion and a P/E ratio of 14.04.
AbbVie (NASDAQ:ABBV) last released its earnings data on Friday, July 26th. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.13. The company had revenue of $4.69 billion for the quarter, compared to the consensus estimate of $4.54 billion. The company’s quarterly revenue was up 4.4% on a year-over-year basis. On average, analysts predict that AbbVie will post $3.13 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 15th. Stockholders of record on Tuesday, October 15th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date of this dividend is Thursday, October 10th.
ABBV has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of AbbVie in a research note to investors on Tuesday. They set an “outperform” rating on the stock. Separately, analysts at UBS AG raised their price target on shares of AbbVie from $40.00 to $46.00 in a research note to investors on Friday, September 27th. They now have a “neutral” rating on the stock. Finally, analysts at Argus initiated coverage on shares of AbbVie in a research note to investors on Monday, August 12th. They set a “buy” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. AbbVie has a consensus rating of “Buy” and an average price target of $47.67.
AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.